Abstract:Purpose: Our purpose was to evaluate hippocampal doses and target volume coverage with and without hippocampal sparing when treating multiple brain metastases using various stereotactic radiosurgery (SRS) platforms. Methods and materials: We selected 10 consecutive patients with 14 separate treatments who had been treated in our department for 3 to 10 brain metastases and added hippocampal avoidance contours. All 14 treatments were planned with GammaPlan for Gamma Knife, Eclipse for single isocenter volumetric modulated arc therapy (VMAT), TomoTherapy Treatment Planning System (TPS) for TomoTherapy, and MultiPlan for CyberKnife. Initial planning was performed with the goal of planning target volume coverage of V100 ≥95% without hippocampal avoidance. If the maximum hippocampal point dose (Dmax) was <6.6 Gy in a single fraction and <40% of the hippocampi received ≤4.5 Gy, no second plan was performed. If either constraint was not met, replanning was performed with these constraints. Results: There was a median of 6 metastases per plan, with an average total tumor volume of 7.32 mL per plan. The median hippocampal Dmax (in Gy) without sparing averaged 1.65, 9.81, 4.38, and 5.46, respectively (P < .0001). Of 14 plans, 3 Gamma Knife and CyberKnife plans required replanning, whereas 13 VMAT and 8 TomoTherapy plans required replanning. The hippocampal constraints were not achievable in 1 plan on any platform when the tumor was bordering the hippocampus. The mean volume of brain receiving 12 Gy (in mL), which has been associated with symptomatic radionecrosis, was 23.57 with Gamma Knife, 76.77 with VMAT, 40.86 with CyberKnife, and 104.06 with TomoTherapy (P = .01). The overall average conformity indices for all plans ranged from 0.36 to 0.52. Conclusions: Even with SRS, the hippocampi can receive a considerable dose; however, if the hippocampi are outlined as organs of risk, sparing these structures is feasible in nearly all situations with all 4 platforms, without detriment to target coverage, and should be considered in all patients undergoing SRS for multiple brain metastases. Summary: Hippocampi play an important role in memory, and sparing of these structures in whole brain radiation can improve neurocognitive outcomes. The hippocampi are not routinely spared when using stereotactic radiosurgery. We evaluated the incidental dose to the hippocampi when treating multiple brain metastases and sought to examine if hippocampal sparing is feasible without detriment to target coverage. We found that hippocampal sparing is possible without affecting coverage or conformality in most cases across treatment platforms.

Dosimetric Study and Neurocognitive Function of Hippocampal-Sparing Whole-Brain Radiotherapy

HELICAL TOMOTHERAPY FOR WHOLE-BRAIN IRRADIATION WITH INTEGRATED BOOST TO MULTIPLE BRAIN METASTASES: DOSIMETRIC ANALYSISANDCLINICAL OUTCOMES

HIPPOCAMPAL AVOIDANCE WHOLE BRAIN RADIATION THERAPY (HA-WBRT) PLUS SIMULTANEOUS INTEGRATED BOOST (SIB) TO GROSS DISEASE: AN ALTERNATIVE TO WHOLE BRAIN RADIATION (WBRT) WITH STEREOTACTIC RADIOSURGERY (SRS)?

Hippocampal sparing in whole-brain radiotherapy for brain metastases: controversy, technology and the future

Simultaneously Avoiding the Hippocampus and Hypothalamic-Pituitary Axis During Whole Brain Radiotherapy: A Planning Study.

A Radiological Analysis Of Oncological Safety Of Whole Brain Radiation Therapy With Hippocampus Avoidance In Patients With Brain Metastasis

Dosimetric and radiobiological comparison of IMRT, VMAT, and helical tomotherapy planning techniques in hippocampal sparing whole brain radiotherapy with simultaneous integrated boost for multiple brain metastases

TIPS-06 ADVANCING BEYOND THE HIPPOCAMPUS TO PRESERVE COGNITION FOR PATIENTS WITH BRAIN METASTASES: DOSIMETRIC RESULTS FROM A PHASE 2 TRIAL OF MEMORY-AVOIDANCE WHOLE BRAIN RADIOTHERAPY

Feasibility Study on Protection of Key Organs in the Whole Brain Radiotherapy with Simultaneous Integrated Boost in Patients with 1-3 Brain Metastases

Radiological Distribution of Brain Metastases and Its Implication for the Hippocampus Avoidance in Whole Brain Radiotherapy Approach

Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001

Hippocampal-Sparing Whole-Brain Radiotherapy for Lung Cancer

Early experience with hippocampal avoidance whole brain radiation therapy and simultaneous integrated boost for brain metastases

Optimization of hippocampus sparing during whole brain radiation therapy with simultaneous integrated boost-tutorial and efficacy of complete directional hippocampal blocking

Ncog-04. Memory Tract Sparing Using Diffuse Tensor Imaging In Radiation Planning Of Primary Brain Tumors

Hippocampal subfield volumetric changes after radiotherapy for brain metastases

Dosimetric comparison of hippocampal-sparing technologies in patients with low-grade glioma

Radiological Features of Non-Small-cell Lung Cancer with Brain Metastases in a Single Center: an Implication for the HA-WBRT Approach

Dosimetric Evaluation Of Intensity-Modulated Radiotherapy, Volumetric Modulated Arc Therapy, And Helical Tomotherapy For Hippocampal-Avoidance Whole Brain Radiotherapy

Hippocampal-sparing and target volume coverage in treating 3 to 10 brain metastases: A comparison of Gamma Knife, single-isocenter VMAT, CyberKnife, and TomoTherapy stereotactic radiosurgery

Assessment of different head tilt angles in volumetric modulated arc therapy for hippocampus-avoidance whole-brain radiotherapy